Evidence map›Paper›PMID 42431899›Full record

ArticleNature communications2026

InstaNovo-P: a de novo peptide sequencing model for phosphoproteomics.

Jesper Lauridsen, Vahap Canbay, Rachel Catzel, Pathmanaban Ramasamy, Amandla Mabona, Kevin Eloff, Paul Fullwood, Jennifer Ferguson, Annekatrine Kirketerp-Møller, Ida Sofie Goldschmidt and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Generalizable Direct Protein Sequencing With InstaNexus.Molecular & cellular proteomics : MCP · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jesper Lauridsen *Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0009-0008-9296-2392
Vahap Canbay *Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0002-5218-2315
Rachel Catzel *InstaDeep Ltd, London, UK.ORCID http://orcid.org/0000-0002-2983-9833
Pathmanaban Ramasamy *CompOmics, VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.ORCID http://orcid.org/0000-0003-4039-5230
Amandla MabonaInstaDeep Ltd, London, UK.ORCID http://orcid.org/0009-0009-7514-677X
Kevin EloffInstaDeep Ltd, London, UK.ORCID http://orcid.org/0000-0003-1355-8743
Paul FullwoodDivision of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, Manchester, UK.
Jennifer FergusonDivision of Molecular and Cellular Function, School of Biological Science, Faculty of Biology Medicine and Health (FBMH), The University of Manchester, Manchester, UK.
Annekatrine Kirketerp-MøllerDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0009-0008-3738-1034
Ida Sofie GoldschmidtDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0009-0005-1325-7969
Tine ClaeysCompOmics, VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.ORCID http://orcid.org/0000-0001-9408-488X
Sam van PuyenbroeckCompOmics, VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.
Nicolas Lopez CarranzaInstaDeep Ltd, London, UK.ORCID http://orcid.org/0000-0003-2235-5753
Erwin M SchoofDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0002-3117-7832
Lennart MartensCompOmics, VIB Center for Medical Biotechnology, VIB, Ghent, Belgium.ORCID http://orcid.org/0000-0003-4277-658X
Jeroen Van GoeyInstaDeep Ltd, London, UK.ORCID http://orcid.org/0000-0003-4480-5567
Chiara FrancavillaDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID http://orcid.org/0000-0003-1775-3386
Timothy Patrick JenkinsDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. tpaje@dtu.dk.ORCID http://orcid.org/0000-0003-2979-5663
Konstantinos KalogeropoulosDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. konka@dtu.dk.ORCID http://orcid.org/0000-0003-3907-9281

Funding

Det Frie Forskningsråd (Danish Council for Independent Research) 4257-00010BLEO Pharma Research Foundation LF-OC-23-001220Novo Nordisk Fonden (Novo Nordisk Foundation) NNF16OC0020670Novo Nordisk Fonden (Novo Nordisk Foundation) NNF22OC0070845Wellcome TrustWellcome Trust (Wellcome) 107636/Z/15/AWellcome Trust (Wellcome) 107636/ Z/15/Z
6 · The paper itself

Abstract

Phosphorylation, a crucial post-translational modification (PTM), plays a central role in cellular signaling and disease mechanisms. Mass spectrometry-based phosphoproteomics is widely used for system-wide characterization of phosphorylation events. However, traditional methods struggle with accurate phosphorylated site localization, complex search spaces, and detecting sequences outside the reference database. Advances in de novo peptide sequencing offer opportunities to address these limitations, but have yet to become integrated and adapted for phosphoproteomics datasets. Here, we present InstaNovo-P, a phosphorylation specific version of our transformer-based InstaNovo model, fine-tuned on extensive phosphoproteomics datasets. InstaNovo-P surpasses existing methods in phosphorylated peptide detection and phosphorylated site localization accuracy across multiple datasets, including complex experimental scenarios. Our model robustly identifies peptides with single and multiple phosphorylated sites, effectively localizing phosphorylation events on serine, threonine, and tyrosine residues. We experimentally validate our model predictions by studying FGFR2 signaling, further demonstrating that InstaNovo-P uncovers phosphorylated sites previously missed by traditional database searches. These predictions align with critical biological processes, confirming the model's capacity to yield valuable biological insights. InstaNovo-P adds value to phosphoproteomics experiments by effectively identifying biologically relevant phosphorylation events without prior information, providing a powerful analytical tool for the dissection of signaling pathways.

Indexed as

PhosphopeptidesPhosphoproteinsProteomicsSequence Analysis, ProteinAmino Acid SequenceHumansMass SpectrometryPhosphorylationProtein Processing, Post-TranslationalReceptor, Fibroblast Growth Factor, Type 2Signal TransductionPhosphopeptidesPhosphoproteinsReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID42431899
PMCPMC13526794

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.